|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.870 USD | -1.02% |
|
-13.04% | +34.90% |
| 02-03 | Obesity stocks slump on Novo's underwhelming 2026 sales forecast | RE |
| 01-28 | Barclays Initiates Coverage on Altimmune With Overweight Rating, $20 Price Target | MT |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
 | 9 | |||||||
| 15 | |||||||
| 18 | |||||||
| 20 | |||||||
| 19 | |||||||
| 24 | |||||||
| 13 | |||||||
| 17 | |||||||
| 21 | |||||||
| 18 | |||||||
| 13 | |||||||
| 15 | |||||||
| - | - | - | 1 | ||||
| 12 | |||||||
| 6 | |||||||
| 17 | |||||||
| 9 | |||||||
| Average | 15 | |||||||
| Weighted average by Cap. | 16 |
- Stock Market
- Equities
- ALT Stock
- Sector Altimmune, Inc.
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition